A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
Price : $35 *
At a glance
- Drugs ASP 8477 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Acronyms MOBILE
- Sponsors Astellas Pharma Europe Ltd
- 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2015 Planned End Date changed from 1 Jun 2015 to 1 Apr 2015 according to ClinicalTrials.gov record.
- 20 Jan 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Apr 2015 according to ClinicalTrials.gov record